Banishree Saha
Research Subjects
Banishree Saha has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amit Choudhury
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publications Håkan Wennbo
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publicationsJay Tang
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publicationsJie Cheng
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publicationsSachin Kumar
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publicationsVinayagam Arunachalam
Takeda Development Center Americas, Inc Cambridge Massachusetts
2 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (9) , e90124
Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis
Objective: This post hoc analysis evaluated the effect of zasocitinib, an investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 (TYK2) inhibitor in late‐stage clinical development, on TYK2 signaling response and disease‐related biomarkers and the association of these changes with clinical response in patients with active psoriatic arthritis from a phase 2b trial (NCT05153148). Methods: Blood samples were collected predose from patients receiving zasocitinib 15 mg, 30 mg, or placebo once daily on Day 1 (baseline), Week 4, and Week 12. Plasma biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, cartilage/bone turnover, and bone formation were measured using Olink Explore HT, Olink Target 48, or Nordic BioScience platforms. Results: As early as Week 4 and through Week 12, in patients receiving zasocitinib 15 or 30 mg, reductions in analyzed biomarkers were observed. Among American College of Rheumatology 20% improvement criteria (ACR20) and Psoriasis Area and Severity Index 75% improvement criteria (PASI 75) responders, reductions in TYK2‐ and skin‐joint‐related biomarkers occurred following zasocitinib treatment from baseline to Week 12. Maintenance of baseline bone formation biomarkers was observed in ACR20 responders receiving zasocitinib. Patients with high baseline levels (≥ median) of TYK2‐ and skin‐joint‐related biomarkers receiving zasocitinib achieved greater ACR20 and PASI 75 response rates than those receiving placebo. Conclusion: Reductions in biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, and cartilage/bone turnover, along with maintenance of bone formation biomarkers at Week 4, occurred following zasocitinib treatment; associations with clinical response (ACR20 and PASI 75) were observed. image
- 14 September 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (9) , e90124
Open AccessImpact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis
Objective: This post hoc analysis evaluated the effect of zasocitinib, an investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 (TYK2) inhibitor in late‐stage clinical development, on TYK2 signaling response and disease‐related biomarkers and the association of these changes with clinical response in patients with active psoriatic arthritis from a phase 2b trial (NCT05153148). Methods: Blood samples were collected predose from patients receiving zasocitinib 15 mg, 30 mg, or placebo once daily on Day 1 (baseline), Week 4, and Week 12. Plasma biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, cartilage/bone turnover, and bone formation were measured using Olink Explore HT, Olink Target 48, or Nordic BioScience platforms. Results: As early as Week 4 and through Week 12, in patients receiving zasocitinib 15 or 30 mg, reductions in analyzed biomarkers were observed. Among American College of Rheumatology 20% improvement criteria (ACR20) and Psoriasis Area and Severity Index 75% improvement criteria (PASI 75) responders, reductions in TYK2‐ and skin‐joint‐related biomarkers occurred following zasocitinib treatment from baseline to Week 12. Maintenance of baseline bone formation biomarkers was observed in ACR20 responders receiving zasocitinib. Patients with high baseline levels (≥ median) of TYK2‐ and skin‐joint‐related biomarkers receiving zasocitinib achieved greater ACR20 and PASI 75 response rates than those receiving placebo. Conclusion: Reductions in biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, and cartilage/bone turnover, along with maintenance of bone formation biomarkers at Week 4, occurred following zasocitinib treatment; associations with clinical response (ACR20 and PASI 75) were observed. image
- Open Access
- 11 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (5) , 1399-1403.e11
Molecular, histological, and clinical effects of selective TYK2 inhibition with zasocitinib (TAK-279) in patients with moderate-to-severe plaque psoriasis
- 11 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (5) , 1399-1403.e11
Open AccessMolecular, histological, and clinical effects of selective TYK2 inhibition with zasocitinib (TAK-279) in patients with moderate-to-severe plaque psoriasis